Literature DB >> 32675421

Remote Administration of the MDS-UPDRS in the Time of COVID-19 and Beyond.

Ruth B Schneider1,2, Taylor L Myers2, Christopher G Tarolli1,2, Katherine Amodeo1, Jamie L Adams1,2, Stella Jensen-Roberts2, E Ray Dorsey1,2.   

Abstract

Entities:  

Keywords:  Parkinson’s disease; coronavirus; telemedicine

Mesh：

Year:  2020        PMID： 32675421     DOI： 10.3233/JPD-202121

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN： 1877-7171            Impact factor:   5.568


× No keyword cloud information.
  10 in total

1.  Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.

Authors:  Sheng Luo; Christopher G Goetz; Dongrak Choi; Sanket Aggarwal; Tiago A Mestre; Glenn T Stebbins
Journal:  Mov Disord       Date:  2022-06-18       Impact factor: 9.698

2.  Feasibility, Safety, and Effectiveness of Telerehabilitation in Mild-to-Moderate Parkinson's Disease.

Authors:  Edoardo Bianchini; Camilla Onelli; Carmen Morabito; Marika Alborghetti; Domiziana Rinaldi; Paolo Anibaldi; Adriano Marcolongo; Marco Salvetti; Francesco E Pontieri
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

3.  Identifying and characterising sources of variability in digital outcome measures in Parkinson's disease.

Authors:  George Roussos; Teresa Ruiz Herrero; Derek L Hill; Ariel V Dowling; Martijn L T M Müller; Luc J W Evers; Jackson Burton; Adrian Derungs; Katherine Fisher; Krishna Praneeth Kilambi; Nitin Mehrotra; Roopal Bhatnagar; Sakshi Sardar; Diane Stephenson; Jamie L Adams; E Ray Dorsey; Josh Cosman
Journal:  NPJ Digit Med       Date:  2022-07-15

Review 4.  Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?

Authors:  Jiang-Fan Chen; Michael A Schwarzschild
Journal:  Parkinsonism Relat Disord       Date:  2020-12-19       Impact factor: 4.891

5.  Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson's disease.

Authors:  Birgul Balci; Burcin Aktar; Sinan Buran; Melike Tas; Berril Donmez Colakoglu
Journal:  Int J Rehabil Res       Date:  2021-06-01       Impact factor: 1.832

Review 6.  The state of telemedicine for persons with Parkinson's disease.

Authors:  Robin van den Bergh; Bastiaan R Bloem; Marjan J Meinders; Luc J W Evers
Journal:  Curr Opin Neurol       Date:  2021-08-01       Impact factor: 6.283

7.  Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy.

Authors:  Davide Pareyson; Chiara Pantaleoni; Roberto Eleopra; Giuseppe De Filippis; Isabella Moroni; Elena Freri; Federica Zibordi; Sara Bulgheroni; Emanuela Pagliano; Daniela Sarti; Antonio Silvani; Licia Grazzi; Pietro Tiraboschi; Giuseppe Didato; Elena Anghileri; Anna Bersano; Laura Valentini; Sylvie Piacentini; Cristina Muscio; Matilde Leonardi; Caterina Mariotti; Marica Eoli; Sara Nuzzo; Fabrizio Tagliavini; Paolo Confalonieri; Francesca De Giorgi
Journal:  Neurol Sci       Date:  2021-04-30       Impact factor: 3.307

8.  Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project.

Authors:  Michael L Alosco; Megan L Mariani; Charles H Adler; Laura J Balcer; Charles Bernick; Rhoda Au; Sarah J Banks; William B Barr; Sylvain Bouix; Robert C Cantu; Michael J Coleman; David W Dodick; Lindsay A Farrer; Yonas E Geda; Douglas I Katz; Inga K Koerte; Neil W Kowall; Alexander P Lin; Daniel S Marcus; Kenneth L Marek; Michael D McClean; Ann C McKee; Jesse Mez; Joseph N Palmisano; Elaine R Peskind; Yorghos Tripodis; Robert W Turner; Jennifer V Wethe; Jeffrey L Cummings; Eric M Reiman; Martha E Shenton; Robert A Stern
Journal:  Alzheimers Res Ther       Date:  2021-08-12       Impact factor: 8.823

9.  Protocol for randomized controlled trial to evaluate the safety and feasibility of a novel helmet to deliver transcranial light emitting diodes photobiomodulation therapy to patients with Parkinson's disease.

Authors:  Claire McGee; Ann Liebert; Geoffrey Herkes; Brian Bicknell; Vincent Pang; Craig S McLachlan; Hosen Kiat
Journal:  Front Neurosci       Date:  2022-08-17       Impact factor: 5.152

10.  Lockdown effects on Parkinson's disease during COVID-19 pandemic: a pilot study.

Authors:  Marika Falla; Alessandra Dodich; Costanza Papagno; Alessandro Gober; Pamela Narduzzi; Enrica Pierotti; Markus Falk; Francesca Zappini; Carlo Colosimo; Luca Turella
Journal:  Acta Neurol Belg       Date:  2021-07-01       Impact factor: 2.396
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.